Article
This article summarizes key data presented during a virtual OncLive® Scientific Interchange & Workshop in which oncologists who specialize in lung cancer treatment discussed their practices for HER2 testing and the potential role of emerging antibody-drug conjugates and novel HER2-targeted small-molecule tyrosine kinase inhibitors for treatment of HER2-altered NSCLC.